Placing the patient at the centre of the drug development paradigm
Patient engagement through advisory boards, surveys, and listening sessions can help address industry challenges such as trial delays.
Drug Development
ACC 25: GLP-1 receptor agonists emerge for treating atrial fibrillation
FDA removes clinical hold on Entrada’s Duchenne therapy
AstraZeneca’s Imfinzi bladder cancer regimen improves survival in Phase III trial
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Allakos cuts 75% of workforce after chronic hives trial failure
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
